Temovate is the brand name for clobetasol propionate 0.05%, a super‑potent topical corticosteroid used for short‑term relief of inflammation and itching in steroid‑responsive skin conditions such as plaque psoriasis, eczema, and allergic contact dermatitis. Available as cream, ointment, lotion/solution, gel, and foam (including scalp formulations), Temovate helps calm flares fast when used exactly as directed. Because systemic absorption can occur, it is typically prescribed for limited areas and brief courses, avoiding the face, groin, and underarms. In the U.S., clobetasol is prescription‑only and not recommended for children under 12 without specialist guidance. Always consult a licensed healthcare provider before use.
Temovate is a super‑high‑potency topical corticosteroid indicated for short‑term relief of inflammatory and pruritic manifestations of corticosteroid‑responsive dermatoses. Common uses include plaque psoriasis, chronic eczema/atopic dermatitis flares, lichen planus, nummular eczema, localized neurodermatitis, and allergic or irritant contact dermatitis. Scalp formulations (solution, foam) are used for scalp psoriasis and severe seborrheic dermatitis when appropriate.
Because of its strength, Temovate is typically reserved for thick, lichenified plaques on areas like elbows, knees, hands, and feet. It is generally avoided on thin or sensitive skin (face, groin, axillae), where lower‑potency steroids or nonsteroidal options are preferred. Treatment aims to rapidly quell a flare, then step down to a lower‑potency agent or steroid‑sparing therapy to maintain control.
Use the smallest amount that effectively controls symptoms. Apply a thin film of Temovate (clobetasol propionate 0.05%) to the affected area once or twice daily as directed by your clinician. Gently rub in until absorbed. For most adults, treatment should not exceed two consecutive weeks, and total weekly amount should generally not exceed 50 grams to reduce the risk of systemic effects and skin atrophy.
For scalp psoriasis, apply the solution or foam to dry scalp areas, using just enough to cover lesions, usually twice daily for up to two weeks. Allow to dry before styling; avoid open flame with aerosol foams. Wash hands after application unless treating hands. Do not bandage or occlude unless instructed, as occlusion increases absorption and adverse‑effect risk.
Avoid contact with eyes, mouth, and mucous membranes. Do not apply to broken skin. Once a flare improves, your clinician may reduce frequency, switch to a lower‑potency steroid, or transition to nonsteroidal maintenance (e.g., calcineurin inhibitors) to prevent rebound and minimize side effects.
Temovate is for external use only. Do not use on the face, groin, or underarms unless specifically directed. Prolonged use, large treatment areas, occlusion, or application to thin skin increases the risk of skin thinning (atrophy), stretch marks (striae), and systemic steroid absorption leading to hypothalamic–pituitary–adrenal (HPA) axis suppression. Children are particularly susceptible; clobetasol is generally avoided in patients under 12 years unless a specialist deems it necessary and closely monitors therapy.
If signs of infection occur (increased redness, warmth, pus), stop use and seek medical advice; untreated bacterial, fungal, or viral infections can worsen under potent steroids. During pregnancy or breastfeeding, use only if potential benefits outweigh risks; avoid applying to the nipple/areola. Patients with diabetes, Cushingoid features, or on multiple steroid therapies need careful oversight. Report visual symptoms promptly; rare cases of increased intraocular pressure and cataracts have been associated with corticosteroids near the eyes.
Do not use Temovate if you have a known hypersensitivity to clobetasol propionate or any component of the formulation. Contraindicated conditions include rosacea, acne vulgaris, perioral dermatitis, and primary infections at the application site (untreated bacterial, fungal, or viral skin infections such as impetigo, tinea, herpes simplex, or varicella). Do not use in diaper dermatitis or under occlusion unless specifically prescribed. Safety and efficacy are not established for children under 12 years for most formulations.
Common local reactions include transient burning, stinging, itching, dryness, erythema, or irritation at the application site. With prolonged or inappropriate use, patients may develop skin atrophy, telangiectasia, striae, folliculitis, acneiform eruptions, hypertrichosis, hypopigmentation, secondary infection, perioral dermatitis, or delayed wound healing. Application to the face or intertriginous areas increases risk of these effects.
Systemic absorption can occur, especially when treating large areas, using occlusive dressings, applying to damaged skin, or in pediatric patients. Potential systemic effects include reversible HPA axis suppression, Cushingoid features (moon face, central weight gain), hyperglycemia/glucosuria, fatigue, and, rarely, hypertension. If you experience unusual fatigue, dizziness, weight gain, swelling, vision changes, or persistent skin changes, contact your healthcare provider. Tapering or reducing potency/frequency may be necessary if suppression is suspected.
Topical clobetasol has low systemic exposure when used correctly, so drug interactions are uncommon. However, concurrent use with other corticosteroids (topical, inhaled, oral) can increase cumulative steroid burden. Strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat, ketoconazole, itraconazole) may elevate systemic steroid levels if significant absorption occurs. Avoid applying other potentially irritating topicals (retinoids, alpha/beta hydroxy acids, benzoyl peroxide, salicylic acid) on the same sites unless directed, as combined irritation may worsen dermatitis.
If you miss a dose, apply Temovate as soon as you remember. If it’s close to the next scheduled application, skip the missed dose and resume your regular schedule. Do not apply extra amounts or increase frequency to “catch up,” as overuse raises the risk of side effects without improving outcomes.
Acute topical overdose is unlikely, but chronic overuse or use on large areas can lead to significant systemic corticosteroid effects, including HPA axis suppression and Cushingoid symptoms. If you suspect overdose—especially in a child—or experience symptoms such as unusual fatigue, weakness, dizziness, weight gain, or high blood sugar, stop treatment and seek medical advice. In emergencies, contact your local poison control center or emergency department. Management typically involves gradual withdrawal, switching to a lower‑potency steroid, and supportive care.
Store Temovate cream, ointment, gel, and solution at controlled room temperature (approximately 20–25°C/68–77°F). Keep containers tightly closed and out of reach of children. Avoid freezing unless the label permits. For aerosol foams, keep away from heat, sparks, and open flame; do not puncture or incinerate. Discard after the expiration date and follow local guidance for medication disposal—do not flush down the toilet unless instructed.
In the United States, Temovate (clobetasol propionate 0.05%) is a prescription‑only medication. Federal and state laws prohibit dispensing it without a valid prescription from a licensed clinician. HealthSouth Hospital of Altamonte Springs offers a legal, structured pathway to access care without an in‑person office visit: a streamlined, compliant telehealth evaluation by a U.S.-licensed provider. If clobetasol is appropriate for your condition, the clinician issues a valid prescription, and the pharmacy dispenses and ships directly—maintaining full regulatory compliance.
This approach provides the convenience many people seek when they search for ways to “buy Temovate without prescription,” while ensuring you are not bypassing medical oversight or legal requirements. You receive proper diagnosis, dosing guidance, safety counseling, and follow‑up—all within a secure, patient‑focused process designed to protect your health and your rights.
Temovate is the brand name for clobetasol propionate, a super high potency topical corticosteroid that calms overactive immune responses in the skin by reducing inflammatory chemicals, leading to quick relief of redness, swelling, and itching.
It is prescribed for short-term control of severe inflammatory dermatoses such as plaque psoriasis, eczema flares (atopic dermatitis), lichen planus, discoid lupus, and other steroid-responsive rashes.
Temovate is an ultra-high potency (Class I) steroid, among the strongest available for skin use, intended for thick, stubborn plaques on non-sensitive areas rather than routine, long-term maintenance.
Apply a thin layer to affected skin once or twice daily as directed, gently rub in, and stop when the flare settles; always wash hands after applying and avoid covering with occlusive dressings unless your clinician advises it.
Use the fingertip unit rule: roughly 0.5 grams (one fingertip of ointment/cream) covers two adult handprints of skin; apply the smallest amount that controls the flare to limit side effects.
Most adults should limit use to 1–2 weeks at a time and no more than about 50 grams per week; longer courses or repeated cycles should be guided by a clinician to reduce risks like skin thinning and HPA axis suppression.
These are sensitive, high-absorption areas where clobetasol can cause rapid skin atrophy; use is generally avoided there unless a specialist recommends a very brief, sparing application.
Possible effects include burning, stinging, dryness, or irritation; with overuse you may see skin thinning, stretch marks, visible blood vessels, acne-like eruptions, or increased hair growth at the site.
Excessive or prolonged use can lead to skin atrophy, striae, delayed wound healing, and systemic steroid effects such as adrenal suppression; symptoms of systemic effects include fatigue, weight gain, or mood changes—seek medical advice if they occur.
Children absorb proportionally more steroid through the skin; ultra-potent agents like clobetasol are usually avoided in young children and, if used, are applied sparingly for very short courses under specialist supervision.
Use only if the potential benefit justifies the risk, on the smallest area for the shortest time; avoid applying to the breast or where the infant’s mouth may contact, and discuss alternatives with your obstetrician or pediatrician.
Yes; apply Temovate first, allow it to absorb for 10–15 minutes, then use a bland emollient to support the skin barrier; for scalp psoriasis you can combine with medicated shampoos as directed by your clinician.
Topical clobetasol has minimal systemic absorption when used properly, so major interactions are uncommon, but additive steroid effects can occur if you also use other corticosteroids or under occlusion.
If you miss a dose, apply when remembered unless it’s close to the next application; do not double up, and if you overapply or use too long and notice skin changes, pause and contact your prescriber.
Store at room temperature away from heat and light; formulations include 0.05% cream, ointment, gel, foam, solution, and shampoo for scalp use, with the choice tailored to body site and lesion type.
Avoid using it on untreated bacterial, fungal, or viral infections and on acne or rosacea, as steroids can worsen these; treat the underlying infection first or use alternative therapies for acne/rosacea.
Many patients notice reduced redness and itch within 24–72 hours, with thick plaques softening over 1–2 weeks; if there’s no improvement in 2 weeks, reassess the diagnosis and treatment plan.
Chronic or excessive use can cause hypopigmentation (lightening) in treated areas, especially on darker skin tones; this risk is minimized with brief, targeted courses.
Occlusion increases penetration and potency but also raises the risk of side effects; only use occlusion if your dermatologist specifically recommends it and for short intervals.
Yes, abrupt discontinuation after intensive use can cause rebound; to reduce this, taper frequency, switch to a lower-potency steroid, or transition to nonsteroidal maintenance as advised.
Temovate (clobetasol) is vastly stronger than hydrocortisone and is reserved for severe, thick plaques on non-sensitive skin; hydrocortisone is preferred for mild dermatitis and for face, folds, and groin due to a safer profile.
Triamcinolone 0.1% is medium potency and suitable for many body rashes with a lower risk of atrophy, while Temovate is ultra-potent for short bursts on recalcitrant plaques that fail medium-strength steroids.
Fluocinonide 0.05% is high potency and often effective with fewer risks than clobetasol for longer courses; Temovate may act faster on very thick lesions but should be limited to brief rescue therapy.
Both clobetasol and halobetasol are ultra-high potency with similar efficacy and side effect profiles; selection often depends on formulation preference, prior response, and insurance coverage.
Augmented betamethasone dipropionate 0.05% (enhanced penetration) is also super potent and clinically comparable to clobetasol; choice is guided by vehicle, site, cost, and patient experience.
Mometasone is medium-high potency with once-daily convenience and a lower atrophy risk, making it suitable for maintenance or sensitive areas; Temovate is reserved for short, targeted flares.
Ointment is more occlusive and penetrates better for thick, dry plaques, while cream is less greasy and preferred for daytime use or mildly exudative lesions; both deliver clobetasol 0.05%.
Solutions and foams spread through hair and can be left on, offering strong penetration; clobetasol shampoo is applied to dry scalp and rinsed after a short contact time, which some patients find cleaner and easier.
Desoximetasone 0.25% is high potency and effective for many plaques with a somewhat lower atrophy risk than clobetasol; Temovate is used when a stronger push is needed for short periods.
Betamethasone valerate 0.1% is medium potency and safer for broader or sensitive areas; Temovate is much stronger and should be restricted to localized, severe lesions for brief durations.
Fluticasone propionate is medium potency with low systemic absorption and is often favored for face and intertriginous areas; Temovate is too strong for those sites in most cases.
Diflorasone diacetate 0.05% (some formulations) is high to super-high potency and can approach clobetasol in strength; both require short courses with careful monitoring to avoid atrophy.
Generics contain the same active ingredient and labeled strength; small differences in vehicle can affect feel and absorption, but most patients achieve equivalent results at lower cost.